PubMed=16099873; DOI=10.1182/blood-2005-03-1167; PMCID=PMC1895110
Pham L.V., Tamayo A.T., Yoshimura L.C., Lin-Lee Y.-C., Ford R.J. Jr.
Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival.
Blood 106:3940-3947(2005)

PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744
Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E., Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Blood 117:200-210(2011)

PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)